Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT05150652
What this trial is testing

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerNode-negative Breast Cancer+1 more
Irada Ibrahim-zada 8
Large-scale testing (Phase 3)Study completedNCT01101438
What this trial is testing

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Who this might be right for
Breast Cancer
Canadian Cancer Trials Group 3,649
Testing effectiveness (Phase 2)Looking for participantsNCT07335081
What this trial is testing

CtDNA in HER2+ EBC Neoadjuvant Treatment

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 60
Post-approval studies (Phase 4)Study completedNCT01301729
What this trial is testing

Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Who this might be right for
Breast Cancer
Hoffmann-La Roche 32
Large-scale testing (Phase 3)Study completedNCT03433313
What this trial is testing

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

Who this might be right for
Breast Cancer
EirGenix, Inc. 807
Not applicableLooking for participantsNCT06035016
What this trial is testing

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

Who this might be right for
HER2-positive Breast CancerEarly-stage Breast Cancer
Peking Union Medical College Hospital 300
Large-scale testing (Phase 3)Study completedNCT00878709
What this trial is testing

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Who this might be right for
Breast Cancer
Puma Biotechnology, Inc. 2,840
Large-scale testing (Phase 3)Study completedNCT02187744
What this trial is testing

PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

Who this might be right for
Early Breast Cancer
Pfizer 226
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06548178
What this trial is testing

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Fudan University 242
Testing effectiveness (Phase 2)UnknownNCT03881878
What this trial is testing

TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery

Who this might be right for
HER2-positive Breast Cancer
Samsung Medical Center 67
Not applicableLooking for participantsNCT07084558
What this trial is testing

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness

Who this might be right for
Early and Locally Advanced Breast Cancer
Austrian Breast & Colorectal Cancer Study Group 350
Not applicableStudy completedNCT07052734
What this trial is testing

Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients

Who this might be right for
Breast Cancer
Sun Yat-sen University 2,843
Not applicableLooking for participantsNCT07211178
What this trial is testing

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Tempus AI 900
Not applicableLooking for participantsNCT06723990
What this trial is testing

Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
European Institute of Oncology 60
Testing effectiveness (Phase 2)Study completedNCT02441946
What this trial is testing

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast CancerHormone Receptor Positive TumorEarly-Stage Breast Carcinoma
Eli Lilly and Company 224
Not applicableStudy completedNCT06907082
What this trial is testing

Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice

Who this might be right for
Breast Cancer
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia 106
Post-approval studies (Phase 4)UnknownNCT05302336
What this trial is testing

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast CancerChemotherapeutic Toxicity
Second Affiliated Hospital, Zhejiang University, School of Medicine 402
Not applicableLooking for participantsNCT06328465
What this trial is testing

FREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

Who this might be right for
Invasive Breast CancerHER2-positive Breast CancerTriple Negative Breast Cancer
European Institute of Oncology 145
Large-scale testing (Phase 3)UnknownNCT05985187
What this trial is testing

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 412
Post-approval studies (Phase 4)Looking for participantsNCT05333328
What this trial is testing

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Who this might be right for
Breast CancerEstrogen Receptor Positive TumorHER2-negative Breast Cancer+2 more
Gangnam Severance Hospital 418
Next Page